三阴性乳腺癌在新辅助化疗中获得病理完全缓解率的Meta分析(英文)

摘要

Objective:The pathological complete response(pCR) rates of neoadjuvant chemotherapy(NAC) in triple-negative breast cancer(TNBC) was reported higher than that in non-TNBC but ranged from 12% to 48%. pCR was reported to be a predictor of long overall survival and exact pCR rate of NAC in TNBC would give us some hints on how to improve outcomes of TNBC patients. The meta-analysis was conducted to estimate the pCR rate of NAC for TNBC through contrasting the pCR rates of TNBC and non-TNBC tumors in NAC. Methods: Studies were selected from the PubMed database and Cochrane Collaboration Library. pCR rates were collected in groups of TNBC and non-TNBC tumors. Review Manager 4.2 was used to perform forest plots and funnel plots. Results: The analysis included 22 studies with 7168 patients, the aggregate pCR rate was 29.5% in TNBC group, which was 17.7% higher than non-TNBC. The summary relative risk(RR) for pCR rate of TNBC group with that of non-TNBC group was 2.55. No obvious statistical heterogeneity and publication bias was detected. Conclusion: This meta-analysis demonstrated that NAC showed a higher pCR rate in TNBC than non-TNBC.